In a study, times to death or relapse (in days) are observed for 23 non-Hodgkins lymphoma (NHL) patients, 11 of whom receiving an allogenic (Allo) transplant from an HLA-matched sibling donor and 12 patients receiving an autologous (Auto) transplant. Also, data on 20 Hodgkins lymphoma (HOD) patients, 5 receiving an allogenic (Allo) transplant from an HLA-matched sibling donor and 15 patients receiving an autologous (Auto) transplant is given.
1. Treating NHL Allo as the baseline hazard function, state the appropriate coding which would allow the investigator to test for any difference in survival functions for the four groups, treating them as four independent groups.
Should I use a p-sample log rank test here?
1. Treating NHL Allo as the baseline hazard function, state the appropriate coding which would allow the investigator to test for any difference in survival functions for the four groups, treating them as four independent groups.
Should I use a p-sample log rank test here?